Prime editing targets GATA2 deficiency in patient-derived blood stem cells
Published in Immunology, Journals, Personalized medicine.
Published October 13, 2026.
Aarhus University’s October 9 research announcement describes experimental correction of a GATA2 defect in blood stem cells taken from a patient. The findings, reported in Science Translational Medicine, concern laboratory gene editing rather than treatment administered to a patient.
GATA2 deficiency can impair immune-cell production and increase susceptibility to infection. The team used prime editing to repair the disease-causing DNA sequence and observed improved function of the affected protein.
Prime editing offers a way to rewrite selected DNA sequences without relying on an intentional double-strand break. This approach still requires careful evaluation of unintended changes and cell function before clinical use.
The researchers identify scale-up as a major next step: editing the much larger number of stem cells needed for an autologous transplant. They must also establish which patients might benefit.
This is a preclinical proof of concept. It does not demonstrate clinical recovery, long-term safety or an available alternative to donor stem-cell transplantation.
Source: Aarhus University, October 9, 2026. Study: Wolff et al., Science Translational Medicine.